Nanoparticle Delivery Systems in Rheumatoid Arthritis: More Than Vehicles

ZHANG Keyi, GUO Yixue, ZENG Xianghu, CAI Bei, ZHANG Junlong, LI Yi, NIU Qian

Abstract

Rheumatoid arthritis (RA) is one of the most prevalent systemic autoimmune inflammatory diseases worldwide, causing chronic, progressively worsening arthritis that may ultimately lead to disability. Despite the availability of numerous therapeutic agents, limitations exhibit, including poor aqueous solubility, suboptimal stability, inadequate permeability, short half-lives, and multi-organ toxicity during long-term or high-dose administration. Nanoparticle-based drug delivery offers a robust strategy to mitigate these deficiencies while maximizing therapeutic efficacy through controlled-release mechanisms and rational administration route design. This review systematically summarizes recent advancements in nanoparticle drug delivery strategies for RA treatment from the perspective of three distinct mechanisms. It details the design rationales, therapeutic principles, and effects of various delivery systems, with particular emphasis on their interactions with the disease microenvironment and the entire body.

 

Keywords: Nanoparticle, Drug delivery, Rheumatoid arthritis, Controlled release, Review

 

Full Text:

PDF


References


FINCKH A, GILBERT B, HODKINSON B, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol, 2022, 18(10): 591-602. doi: 10. 1038/s41584-022-00827-y.

WANG P, ZHANG Y, LEI H, et al. Hyaluronic acid-based M1 macrophage targeting and environmental responsive drug releasing nanoparticle for enhanced treatment of rheumatoid arthritis. Carbohydr Polym, 2023, 316: 121018. doi: 10.1016/j.carbpol.2023.121018.

Di MATTEO A, BATHON J M, EMERY P. Rheumatoid arthritis. Lancet, 2023, 402(10416): 2019-2033. doi: 10.1016/S0140-6736(23) 01525-8.

ALETAHA D, SMOLEN J S. Diagnosis and management of rheumatoid arthritis: a review. JAMA, 2018, 320(13): 1360-1372. doi: 10.1001/jama. 2018.13103.

SMOLEN J S, ALETAHA D, MCINNES I B. Rheumatoid arthritis. Lancet, 2016, 388(10055): 2023-2038. doi: 10.1016/S0140-6736(16) 30173-8.

MARCUCCI E, BARTOLONI E, ALUNNO A, et al. Extra-articular rheumatoid arthritis. Reumatismo, 2018, 70(4): 212-224. doi: 10.4081/reumatismo.2018.1106.

RIDGLEY L A, ANDERSON A E, PRATT A G. What are the dominant cytokines in early rheumatoid arthritis? Curr Opin Rheumatol, 2018, 30(2): 207-214. doi: 10.1097/BOR.0000000000000470.

MCINNES I B, SCHETT G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol, 2007, 7(6): 429-442. doi: 10. 1038/nri2094.

MATEEN S, ZAFAR A, MOIN S, et al. Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin Chim Acta, 2016, 455: 161-171. doi: 10.1016/j.cca.2016.02.010.

WEN J, LI H, DAI H, et al. Intra-articular nanoparticles based therapies for osteoarthritis and rheumatoid arthritis management. Mater Today Bio, 2023, 19: 100597. doi: 10.1016/j.mtbio.2023.100597.

GUO R, WANG L, HUANG J, et al. Ultrasound-targeted microbubble destruction-mediated cell-mimetic nanodrugs for treating rheumatoid arthritis. ACS Biomater Sci Eng, 2023, 9(6): 3670-3679. doi: 10.1021/acsbiomaterials.3c00475.

AMAN R M, ZAGHLOUL R A, ELSAED W M, et al. In vitro-in vivo assessments of apocynin-hybrid nanoparticle-based gel as an effective nanophytomedicine for treatment of rheumatoid arthritis. Drug Deliv Transl Res, 2023, 13(11): 2903-2929. doi: 10.1007/s13346-023-01360-5.

DING Q, HU W, WANG R, et al. Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduct Target Ther, 2023, 8(1): 68. doi: 10.1038/s41392-023-01331-9.

SMOLEN J S, ALETAHA D, BIJLSMA J W J, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis, 2010, 69(4): 631-637. doi: 10.1136/ard.2009.123919.

PINCUS T, YAZICI Y, SOKKA T, et al. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol, 2003, 21(5 Suppl 31): S179-S185.

DOUMEN M, PAZMINO S, BERTRAND D, et al. Glucocorticoids in rheumatoid arthritis: balancing benefits and harm by leveraging the therapeutic window of opportunity. Joint Bone Spine, 2023, 90(3): 105491. doi: 10.1016/j.jbspin.2022.105491.

GRAUDAL N, JÜRGENS G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum, 2010, 62(10): 2852-2863. doi: 10. 1002/art.27592.

WASSENBERG S, RAU R, STEINFELD P, et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum, 2005, 52(11): 3371-3380. doi: 10.1002/art.21421.

WANG W, ZHOU H, LIU L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur J Med Chem, 2018, 158: 502-516. doi: 10.1016/j.ejmech.2018.09.027.

GUPTA A, LEE J, GHOSH T, et al. Polymeric hydrogels for controlled drug delivery to treat arthritis. Pharmaceutics, 2022, 14(3): 540. doi: 10. 3390/pharmaceutics14030540.

TANG Y, WU Z, GUO R, et al. Ultrasound-augmented anti-inflammatory exosomes for targeted therapy in rheumatoid arthritis. J Mater Chem B, 2022, 10(38): 7862-7874. doi: 10.1039/d2tb01219g.

HUA C, BUTTGEREIT F, COMBE B. Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open, 2020, 6(1): e000536. doi: 10.1136/rmdopen-2017-000536.

HOES J N, JACOBS J W, BOERS M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis, 2007, 66(12): 1560-1567. doi: 10.1136/ard.2007.072157.

EMERY P, POPE J E, KRUGER K, et al. Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: a systematic review. Adv Ther, 2018, 35(10): 1535-1563. doi: 10.1007/s12325-018-0757-2.

SMOLEN J S, LANDEWÉ R B M, BERGSTRA S A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis, 2023, 82(1): 3-18. doi: 10.1136/ard-2022-223356.

WANG F, SUN L, WANG S, et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc, 2020, 95(7): 1404-1419. doi: 10.1016/j.mayocp.2020.01.039.


Refbacks

  • There are currently no refbacks.